In This Issue
Cancer Discov February 1 2018 8 (2) 127-129; DOI:10.1158/2159-8290.CD-ITI8-2
cfDNA profiling has high concordance with direct tumor sequencing in 1,397 patients with advanced colorectal cancer and uncovers EGFR ECD mutations that may drive resistance to anti-EGFR antibodies.
Analysis of somatic mutational data in large patient cohorts uncovered rare hotspots that may accelerate the discovery of rare driver mutations in cancer and guide selection of targeted therapies.
The ERK inhibitor ulixertinib is well tolerated and achieved partial responses in patients with NRAS-, BRAFV600-, and non-V600 BRAF-mutant advanced solid tumors in a phase I clinical trial.
Mouse- and patient-derived organotypic tumor spheroids model the tumor-immune microenvironment to predict response and resistance to anti–PD-1 and evaluate potential combination therapies.
CDK4/6 inhibitors derepress NFAT to promote IL2 secretion, enhance T-cell activation and tumor infiltration, and cooperate with anti–PD-1 antibodies to boost antitumor immunity in vivo.
Gastrointestinal stromal tumors exhibit a transcriptional dependence on FOXF1, which binds enhancers to promote expression of genes, including ETV1 and KIT, required for tumor growth.